Selenium Nicotinate

Selenium nicotinate is a compound combining selenium with nicotinic acid (niacin), theorized to enhance selenium bioavailability through organic chelation. No human clinical trials have established health benefits specific to this form, distinguishing it from better-studied selenium compounds like selenomethionine or sodium selenite.

Origin & History

Selenium nicotinate is a synthetic organoselenium compound with the chemical formula C6H4NO2Se, classified as an ester of nicotinic acid (niacin) and selenium. It is chemically synthesized rather than extracted from natural sources, distinguishing it from elemental selenium or natural mineral forms.

Historical & Cultural Context

No evidence of selenium nicotinate in traditional medicine systems was found, as it appears to be a modern synthetic compound without historical context. The compound lacks any documented traditional uses, unlike some naturally occurring minerals used in herbal medicine systems.

Health Benefits

• No human health benefits established - no clinical trials, RCTs, or meta-analyses were identified in the research
• Microbial enzyme studies show selenium acts as a cofactor in nicotinic acid hydroxylase, but this is bacterial research only
• No evidence quality available due to absence of human studies
• No documented therapeutic effects in humans
• Safety and efficacy remain unestablished for human supplementation

How It Works

Selenium nicotinate is hypothesized to deliver selenium as a cofactor for selenoproteins, including glutathione peroxidases (GPx1-4) and thioredoxin reductase (TrxR1), which neutralize reactive oxygen species via reduction of hydrogen peroxide and lipid hydroperoxides. The nicotinate moiety may theoretically improve intestinal absorption compared to inorganic selenite by facilitating transport through organic acid pathways, though this has not been confirmed in human pharmacokinetic studies. In bacterial systems, selenium acts as a cofactor in nicotinic acid hydroxylase, a molybdenum-containing enzyme, but this microbial mechanism has no established human analogue.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on selenium nicotinate were identified. Research is limited to microbial enzymology studies, such as investigations of nicotinic acid hydroxylase from Clostridium barkeri (PMID: 7181513), which are in vitro or bacterial studies rather than human trials.

Clinical Summary

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted specifically on selenium nicotinate as of the available research base. General selenium research in humans involves forms such as selenomethionine and sodium selenite, studied in contexts including cancer prevention (SELECT trial, n=35,533) and thyroid function, with mixed or null results. The absence of human data for selenium nicotinate makes it impossible to assign an evidence quality rating or recommend specific therapeutic dosages. Any extrapolation from general selenium research to this specific compound is speculative without comparative bioavailability studies.

Nutritional Profile

Selenium Nicotinate is a coordination compound combining selenium (Se) with nicotinic acid (niacin/vitamin B3). As a mineral-organic complex, it is not a food source and therefore has no macronutrient content (0g protein, 0g fat, 0g carbohydrate). The compound theoretically delivers two micronutrient components upon dissociation: (1) Selenium — an essential trace mineral; typical supplemental doses in selenium compounds range from 50–200 mcg elemental Se per serving, though no standardized dosing exists specifically for selenium nicotinate; and (2) Nicotinic acid (niacin) — a B-vitamin with an adult RDA of 14–16 mg NE (niacin equivalents). The molar ratio of selenium to nicotinic acid in the complex is not publicly standardized in available literature. Selenium in organic-bound forms (e.g., selenomethionine) generally demonstrates higher bioavailability (~90%) compared to inorganic forms (~50%), but the specific bioavailability of selenium nicotinate in humans has not been studied or documented. The nicotinate moiety is structurally identical to free nicotinic acid, suggesting potential absorption via established niacin transport pathways (sodium-dependent carriers in the intestine), though this remains unconfirmed for this specific chelate. No fiber, antioxidant ORAC values, phytochemical content, or caloric density apply. The compound is primarily characterized in microbial biochemistry as a selenium-containing cofactor in bacterial nicotinic acid hydroxylase enzymes, not as a human nutritional substrate.

Preparation & Dosage

No clinically studied dosage ranges for selenium nicotinate are available as no human trials exist. General selenium supplementation data exists but lacks nicotinate-specific standardization or dosing guidance. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic combinations established due to lack of human studies

Safety & Interactions

Selenium toxicity (selenosis) can occur at chronic intakes above 400 mcg/day in adults, causing hair loss, nail brittleness, gastrointestinal disturbance, and neurological symptoms regardless of selenium form. Selenium compounds may interact with anticoagulants such as warfarin, potentially altering bleeding risk, and may reduce the efficacy of cisplatin-based chemotherapy by modulating oxidative stress pathways. Selenium supplementation is generally approached cautiously during pregnancy, with the Tolerable Upper Intake Level set at 400 mcg/day for adults by the Institute of Medicine, and the nicotinate component introduces additional theoretical niacin-related flushing risk at high doses. Individuals with autoimmune thyroid disease should consult a physician before supplementing, as selenium dose-dependently affects thyroid peroxidase antibody levels.